The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
GenoMed is developing Healthchip, a genomic test for predicting six common cancers: breast, colon, lung, ovarian, pancreatic, and prostate. The test consists of several hundred SNPs that the company reports identifies patients correctly 85% of the time.
Genzyme Corporation has developed a test that detects all secondary BCR-ABL mutations and predicts resistance to Gleevac.
Inverness Medical Innovations acquired CLONDIAG chip technologies GmbH which has developed a multiplexing technology for nucleic acid and immunoassay based diagnostics. Inverness acquires 67.45% of CLONDIAG stock (218,502 shares) for approximately $3.1 million in cash.
Nanogen introduced its NGEN CFTR ASR test designed to detect 23 wild type and mutation sequences associated with cystic fibrosis.
Quest Diagnostics launched LEUMETA to identify and analyze genetic components of leukemia and lymphoma tumors using blood plasma instead of bone marrow. The assays are designed to measure tumor load and to detect certain blood cancer markers including messenger RNA, DNA and protein in plasma.
Stratagene and Bayer are collaborating on the development of a new molecular analyzer. Bayer will purchase customized Mx3005P instrument systems for use in a new platform.
![[Page Banner Image]](images/hmole.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
